A Phase 3 Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Multiple Myeloma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. 1) Patients must have confirmed diagnosis of symptomatic multiple myeloma
    2. 2) Patient has received 3 to 6 cycles of an induction therapy that includes a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) (eg, VTd, RVd) with or without a CD38 monoclonal antibody, or VCd, and followed by a single or tandem ASCT. Patient may also have received post-stem cell transplant consolidation
    3. 3) Participants within 12 months from initiation of induction who achieved at least a PR after ASCT with or without consolidation

You may not be eligible for this study if the following are true:

    1. 1) Participant has progressive disease or clinical relapse following ASCT with or without consolidation or is not responsive to primary therapy
    2. 2) Participant has smoldering myeloma, solitary plasmacytoma or nonsecretory myeloma
    3. 3) Participant has known central nervous system/meningeal involvement of multiple myeloma



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.